63V.F VERICI DX PLC LS-001

Healthcare Biotechnology Frankfurt Exchange
0.0015 EUR
Close of Nov 11, 2026
0.0015 0.0200
Market cap
EUR 9.99M
P/E
-
P/B
1.96x
ROE
-106.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 63V.F undervalued?

Graham number

The Graham number of VERICI DX PLC LS-001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

VERICI DX PLC LS-001 fundamental analysis

No fundamental analysis for VERICI DX PLC LS-001 yet.

VERICI DX PLC LS-001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About VERICI DX PLC LS-001

Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; Clarava, a pre-transplant prognosis test for the risk of early acute rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failur…

Full company profile